

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1.-179. (Canceled).

180. (Previously Presented) A method of administering a beneficial substance to a human or animal subject, said method comprising subcutaneously implanting an implant comprising a resorbable mesoporous silicon carrier material having a beneficial substance associated therewith, wherein the mesoporous silicon carrier material is resorbable or bio-erodible by mammalian subcutaneous physiological fluids.

181. (Previously Presented) A method according to claim 180, wherein the mesoporous silicon has a porosity between about 2% and 80%.

182. (Previously Presented) A method according to claim 180, wherein the mesoporous silicon has a porosity between about 4% and 50%.

183. (Previously Presented) A method according to claim 180, wherein the mesoporous silicon has a porosity of about 30%.

184. (Previously Presented) A method according to claim 180, wherein the beneficial substance is delivered for a month, or two or three months, or a year.

185. (Previously Presented) An implant according to claim 180, wherein the implant may be in the size ranges >0 to 2mm x >0 to 20mm x >0 to 20 mm.

186. (Previously Presented) A method according to claim 180, wherein the mesoporous silicon comprises an element as the beneficial substance which has been impregnated at a concentration between 1 and 90 atomic percent at a depth, from the surface of the sample, between 0.35 μ m and 1000 μ m.

187. (Previously Presented) A method according to claim 186, wherein the element is present at a concentration between 30 μ m and 1000 μ m.

188.-189. (Canceled).

190. (New) A method of administering phosphorous to a human or animal subject, said method comprising subcutaneously implanting an implant comprising a resorbable mesoporous silicon carrier material having a phosphorous associated therewith which has been impregnated at a concentration between 1 and 90 atomic percent at a depth, from the surface of the sample, between 0.35 μ m and 1000 μ m, wherein the mesoporous silicon carrier material is resorbable or bio-erodible by mammalian subcutaneous physiological fluids.

191. (New) A method of administering a platinum anti-cancer substance to a human or animal subject, said method comprising subcutaneously implanting an implant comprising a resorbable mesoporous silicon carrier material having a platinum anti-cancer substance associated therewith, wherein the mesoporous silicon carrier material is resorbable or bio-erodible by mammalian subcutaneous physiological fluids.

192. (New) A method of administering a beneficial substance to a human or animal subject, said method comprising subcutaneously implanting an implant consisting of a resorbable mesoporous silicon carrier material having a beneficial substance associated therewith, wherein the mesoporous silicon carrier material is resorbable or bio-erodible by mammalian subcutaneous physiological fluids.